Abime News Today

Elpiscience Biopharma Ltd. is out-licensing to Astellas Pharma Inc. two preclinical bispecific macrophage engagers – ES-019, an anti-PD-L1/SIRPα bispecific antibody, and another unnamed program – in a deal worth up to $1.7 billion. The deal marks the Shanghai-based company’s first out-licensing deal, Elpiscience CEO Darren Ji told BioWorld, noting that Astellas will have global rights to both molecules with a potential to in-license two more.

Elpiscience Biopharma Ltd. is out-licensing to Astellas Pharma Inc. two preclinical bispecific macrophage engagers – ES-019, an anti-PD-L1/SIRPα bispecific antibody, and another unnamed program – in a deal worth up to $1.7 billion. The deal marks the Shanghai-based company’s first out-licensing deal, Elpiscience CEO Darren Ji told BioWorld, noting that Astellas will have global rights to both molecules with a potential to in-license two more.

Ledger dying and we are thinking about the images was bime -- columbine. >> peter: it casts a cloud and it is so close to columbine. on the phone is the university of denver spokesman. good morning, miss montgomery. >> good morning. >> peter: describe the scene of the family members coming to the hospital to see their loved ones. >> sure, we have 20 patients that were taking care of. their injuries are minor to severe gunshot wounds. majority are adults and teens. families are able to come to th...

Lo, odin we nee room o>> tnk y" formavinrs. bi: yos ene omea ed th te yorin rcumance hat allbiowsyo s al-qeda t comeethe ak um >>cewet ll hsave. -q t bime: i oht wwere k wiing is w.>> h>> tvet a rt ofbi i heo wre swiueg w t atof genelpetrassaidsor gainwereragi -- ra ilnee ra at bidt norwere the inregi -- pross rhap losg be he th. ro we e taapn uroseye of e th ba. e iswee istal-qaa, ne f th talieban. our sarchbas nisishqain nk th liba ta havdo e rr earchchn thisneryh nssu you tan gavt rorch bsit ...